Progesterone in gender-affirming therapy of trans women
- PMID: 35721880
- PMCID: PMC10558402
- DOI: 10.4331/wjbc.v13.i3.66
Progesterone in gender-affirming therapy of trans women
Abstract
Progesterone is an endogenous steroid hormone with an important role for the physiology of the female reproductive system and the mammary gland. It has additional significant actions in other tissues, such as the cardiovascular system, the central nervous system, and bones. The present article explores potential clinical implications from the addition of bioidentical progesterone to gender-affirming treatment of trans women. For this purpose, it provides an overview of the physiological action of progesterone in target tissues and speculates on possible benefits for gender transitioning. Progesterone is expected to exert moderate anti-androgen action through suppression of the hypothalamic-pituitary-gonadal axis and inhibition of the conversion of testosterone to dihydrotestosterone. It may also contribute to breast maturation. In the long-term, progesterone could prevent bone loss and protect cardiovascular health. The potential benefits are mainly inferred by extrapolating evidence from biological actions in cisgender women and medical assumptions and hence, clinicians need to be cautious when applying these data into practice. Further research is needed to ascertain the efficacy and safety of progesterone in current hormonal regimens.
Keywords: Breast; Gender dysphoria; Human; Progesterone; Transgender persons.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors state that they have no conflict of interest to report.
Similar articles
-
Progesterone Is Important for Transgender Women's Therapy-Applying Evidence for the Benefits of Progesterone in Ciswomen.J Clin Endocrinol Metab. 2019 Apr 1;104(4):1181-1186. doi: 10.1210/jc.2018-01777. J Clin Endocrinol Metab. 2019. PMID: 30608551
-
MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.Eur J Endocrinol. 2021 Jun 28;185(2):R49-R63. doi: 10.1530/EJE-21-0059. Eur J Endocrinol. 2021. PMID: 34081614 Review.
-
Gender-Affirming Hormone Therapy Modifies the CpG Methylation Pattern of the ESR1 Gene Promoter After Six Months of Treatment in Transmen.J Sex Med. 2020 Sep;17(9):1795-1806. doi: 10.1016/j.jsxm.2020.05.027. Epub 2020 Jul 4. J Sex Med. 2020. PMID: 32636163
-
Does sex hormone treatment reverse the sex-dependent stress regulation? A longitudinal study on hypothalamus-pituitary-adrenal (HPA) axis activity in transgender individuals.Psychoneuroendocrinology. 2019 Jun;104:228-237. doi: 10.1016/j.psyneuen.2019.02.023. Epub 2019 Mar 14. Psychoneuroendocrinology. 2019. PMID: 30897530
-
Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men.Fertil Steril. 2021 Oct;116(4):936-942. doi: 10.1016/j.fertnstert.2021.07.1206. Epub 2021 Sep 2. Fertil Steril. 2021. PMID: 34481638 Review.
Cited by
-
Distinct mucosal and systemic immunological characteristics in transgender women potentially relating to HIV acquisition.JCI Insight. 2023 Aug 22;8(16):e169272. doi: 10.1172/jci.insight.169272. JCI Insight. 2023. PMID: 37432754 Free PMC article.
-
Estrogen influences class-switched memory B cell frequency only in humans with two X chromosomes.J Exp Med. 2025 Apr 7;222(4):e20241253. doi: 10.1084/jem.20241253. Epub 2025 Mar 6. J Exp Med. 2025. PMID: 40049222 Free PMC article.
-
A mini-review of the evidence for cerebrovascular changes following gender-affirming hormone replacement therapy and a call for increased focus on cerebrovascular transgender health.Front Hum Neurosci. 2023 Nov 22;17:1303871. doi: 10.3389/fnhum.2023.1303871. eCollection 2023. Front Hum Neurosci. 2023. PMID: 38077183 Free PMC article. Review.
-
High-Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018-2019.Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70078. doi: 10.1002/pds.70078. Pharmacoepidemiol Drug Saf. 2025. PMID: 39777815 Free PMC article.
References
-
- MacKenzie SM, van Kralingen JC, Davies E. Regulation of Aldosterone Secretion. Vitam Horm. 2019;109:241–263. - PubMed
-
- Garg D, Ng SSM, Baig KM, Driggers P, Segars J. Progesterone-Mediated Non-Classical Signaling. Trends Endocrinol Metab. 2017;28:656–668. - PubMed
-
- Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev. 1997;18:502–519. - PubMed
-
- Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand. 2015;94 Suppl 161:8–16. - PubMed
Publication types
LinkOut - more resources
Full Text Sources